The Clareon PanOptix (CNWT) IOL is a newer trifocal IOL made from a glistening-free hydrophobic acrylic material incorporating hydroxyethyl methacrylate (HEMA). While its predecessor (TFNT) has established clinical outcomes, long-term data. This study aimed to evaluate the refractive and visual outcomes during a 1-year follow-up after CNWT implantation in one eye, with a different type of refractive multifocal or extended depth of focus IOL in the contralateral eye (mix- and match setting). This was a retrospective, single-arm case series conducted at the single eye clinic, Seoul, Republic of Korea. The study included patients who underwent cataract surgery with mix-and-match IOL implantations, receiving a CNWT in one eye. Data were collected from the eyes with a CNWT. Monocular uncorrected distance visual acuity (UCDVA), corrected distance visual acuity (CDVA), uncorrected near visual acuity (UCNVA), and manifest refraction were analyzed from measurements taken at 1, 3, 6, and 12 months postoperatively. Rates and causes of secondary surgical intervention, such as IOL exchange and toric IOL axis readjustment, were also investigated. Statistical analysis involved Kolmogorov-Smirnov tests for normality and t-tests for comparisons, with p <.05 considered significant. Data from 897 eyes (out of 1282 initially screened) with continuous measurements and no secondary interventional surgeries were included in the primary monocular visual acuity and refractive analysis. UCDVA of LogMAR 0.0 or better increased from 50.91% at 1 month to 85.95% at 12 months. CDVA of LogMAR 0.0 or better improved from 89.52% at 1 month to 98.1% at 12 months. At 12 months, 94.09% of eyes achieved UCNVA of LogMAR 0.1 or better. A slight mean hyperopic shift (+ 0.07D) was observed up to 12 months. Toric CNWT IOLs were used in 71.0% of these eyes, with 88.07% achieving manifest refractive astigmatism of ≤ -0.75D at 12 months. Overall, 85 out of 1282 eyes (6.63%) underwent secondary surgery: 4.45% for IOL exchange and 2.18% for toric IOL axis readjustment. Post-reoperation, UCDVA and UCNVA significantly improved. The new hydrophobic acrylic trifocal IOL (CNWT) with HEMA demonstrated significant improvements in visual acuity and stable refractive outcomes over one year in a mix-and-match setting. The use of toric CNWT IOLs effectively reduced astigmatism. These findings suggest that this IOL is a reliable option for enhancing visual quality and reducing spectacle dependency in this specific implantation context. Despite the low rate of reoperations, the results underscore the ongoing need for advancements in biometric measurements and IOL power calculation formulas to further minimize such interventions.

Purpose: To evaluate clinical and patient‐reported outcomes of the Clareon PanOptix (CP) hydrophobic acrylic trifocal IOL in eyes with previous myopic laser refractive surgery (LRS). Methods: This single‐center, ambispective study included 94 eyes of 47 patients with previous myopic LRS undergoing CP implantation. At 6 months, monocular visual acuity (VA), refraction, and refractive outcomes were assessed. Prediction accuracy was compared using Barrett True‐K and Haigis‐L with conventional keratometry (CK) or total keratometry (TK) on the IOLMaster 700 and Barrett True‐K with CK or TK on the Argos; Argos TK incorporated Pentacam‐measured posterior corneal astigmatism. Spectacle dependence, satisfaction, and visual disturbances were assessed. Correlations between preoperative corneal higher‐order aberrations (HOAs) and postoperative outcomes were analyzed. Results: Mean uncorrected VAs were 0.028 ± 0.087 logMAR for distance, 0.177 ± 0.130 logMAR for intermediate, and 0.093 ± 0.137 logMAR for near. The mean postoperative spherical equivalent was −0.142 ± 0.375 D, with 81% of eyes within ±0.50 D of emmetropia. In a retrospective comparison of IOL power calculation methods, Barrett True‐K with TK on the IOLMaster 700 yielded the highest observed proportion of eyes within ±0.50 D of the intended target (78.7%). After Holm–Bonferroni correction, preoperative corneal HOA RMS and nonspherical HOA RMS at a 3.0‐mm diameter were associated with uncorrected distance VA, whereas corneal HOAs at larger analysis diameters (5.0–6.0 mm) were associated with postoperative visual disturbances. Patients reported high satisfaction (3.09 ± 0.62) and complete spectacle independence for distance and intermediate vision. Conclusions: The CP trifocal IOL is an effective option for presbyopia correction in post‐myopic LRS eyes meeting predefined preoperative corneal aberration criteria. Refractive predictability depended on device‐specific formula–keratometry combinations, with Barrett True‐K yielding the highest observed ±0.50 D rates with TK (IOLMaster 700) and with CK (Argos). Corneal HOA analysis at specified measurement diameters may further guide patient selection and counseling.

Background: We aimed to evaluate the feasibility, safety, and efficiency of Corneal Lenticule Extraction for Advanced Refractive Correction (CLEAR) enhancement performed after primary CLEAR. Methods: Six eyes from five patients underwent enhancement to correct residual myopic error. All procedures were carried out with the low-energy FEMTO LDV Z8 laser platform (Ziemer Ophthalmic Systems AG, Port, Switzerland) equipped with integrated optical coherence tomography enabling precise lenticule positioning. Results: The myopic residual refractive sphere was fully corrected in all cases, with refraction remaining stable over the follow-up period. All eyes showed improvement in uncorrected distance visual acuity after retreatment with CLEAR and achieved 20/20 vision or better at the final follow-up visit. Conclusions: Our results suggest that CLEAR enhancement is a safe and effective option for treating residual myopic refractive error after primary CLEAR, keeping the procedure flapless.